A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
Clinical trial NCT05469113 · COMPLETED
Trial details
- NCT number
- NCT05469113
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-29
- Primary completion
- 2019-03-05
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.